Carvalho Noemia Barbosa, Freitas Vera Lucia Teixeira de, Aikawa Nadia Emi, Vieira Lucas Teixeira, Bezerra Rita Cristina, Proença Adriana Coraccini Tonácio de, Bonfiglioli Karina, Nakanishi Érika Yoshie Shimoda, Higashino Hermes Ryoiti, Shikanai-Yasuda Maria Aparecida
Universidade de São Paulo, Divisão de Moléstias Infecciosas do Hospital das Clinicas da Faculdade de Medicina, São Paulo, SP, Brasil.
Universidade de São Paulo, Departamento de Infectologia e Medicina Tropical da Faculdade de Medicina, São Paulo, SP, Brasil.
Rev Soc Bras Med Trop. 2025 Jun 2;58:e008022025. doi: 10.1590/0037-8682-0419-2024. eCollection 2025.
Patients with chronic Chagas disease (CD) and autoimmune rheumatic disorders (ARD) receiving immunosuppressive therapy are at risk for CD reactivation (CDR). This study monitored parasitemia over 9-121 months in six patients with CD and ARD using conventional and quantitative PCR and parasitology. Five patients showed parasitemia; two had elevated levels of parEq/mL (49-458.7). One patient received benznidazole with a marked decrease in parasitemia; in the other, treatment was discontinued after 12 days due to toxicity. No CDR occurred. These findings support the need for qPCR standardization for preemptive therapy and suggest that benznidazole may prevent CDR in patients with high parasitemia.
患有慢性恰加斯病（CD）且接受免疫抑制治疗的自身免疫性风湿性疾病（ARD）患者存在CD再激活（CDR）风险。本研究使用传统和定量PCR以及寄生虫学方法，对6例患有CD和ARD的患者进行了9至121个月的寄生虫血症监测。5例患者出现寄生虫血症；2例患者的parEq/mL水平升高（49 - 458.7）。1例患者接受苯硝唑治疗后寄生虫血症显著降低；另1例患者因毒性在12天后停药。未发生CDR。这些发现支持对qPCR进行标准化以用于预防性治疗的必要性，并表明苯硝唑可能预防高寄生虫血症患者的CDR。
